

# LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

NCT06018766

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Steven Hays, MD
Enrollment	30 participants

## Key Eligibility Criteria

---

### Inclusion (16)

- Age > 18 years old
  - Recipient of a double pulmonary allograft at least 12 months before study entry
  - Subjects with clinically diagnosed CLAD-BOS phenotype (all 3 required)
  - BOS defined as screening FEV1 between 85-51% of the baseline as defined by the 2 highest FEV1 measures at least 3 weeks apart.
  - Diagnosis within 12 months of screening visit.
- ... and 11 more (see full listing online)

### Exclusion (17)

- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
  - Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  - Patients with re-transplantation or currently listed for re-transplantation
  - Patients with confirmed other causes for loss of lung function, such as acute infection, acute rejection, restrictive allograft syndrome (CLAD - RAS phenotype, see Protocol Specific Definition), etc.
  - Patients with acute antibody-mediated rejection at Screening. In this context, clinically stable patients (as judged by the Investigator) with detectable donor-specific antibodies (DSA) levels at the Screening Visit are eligible for the study
- ... and 12 more (see full listing online)

## Locations (1 total)

---

University of California, San Francisco, San Francisco, California, United States